Matches in Wikidata for { <http://www.wikidata.org/entity/Q91971437> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q91971437 description "2019 թվականի դեկտեմբերի 10-ին հրատարակված գիտական հոդված" @default.
- Q91971437 description "article scientifique publié en 2019" @default.
- Q91971437 description "artículu científicu espublizáu n'avientu de 2019" @default.
- Q91971437 description "im Dezember 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91971437 description "scientific article published on 10 December 2019" @default.
- Q91971437 description "wetenschappelijk artikel" @default.
- Q91971437 description "наукова стаття, опублікована 10 грудня 2019" @default.
- Q91971437 name "Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospect" @default.
- Q91971437 name "Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospect" @default.
- Q91971437 type Item @default.
- Q91971437 label "Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospect" @default.
- Q91971437 label "Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospect" @default.
- Q91971437 prefLabel "Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospect" @default.
- Q91971437 prefLabel "Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospect" @default.
- Q91971437 P1433 Q91971437-FB47F99D-7301-4B00-B715-9EFB211BEFDB @default.
- Q91971437 P1476 Q91971437-69517E21-B3D6-4191-9C2A-E2A14822BA0E @default.
- Q91971437 P2093 Q91971437-07EF00FF-4BF6-42DE-A239-56006E7CBCFC @default.
- Q91971437 P2093 Q91971437-39ED828B-B0CF-498D-9258-3146F91568A5 @default.
- Q91971437 P2093 Q91971437-4C46F383-36F3-41EC-86F4-A37E0CEAFA83 @default.
- Q91971437 P2093 Q91971437-5CF431AD-30FF-4066-BFC7-B2FA3F1CB4FE @default.
- Q91971437 P2093 Q91971437-681DD0E8-4661-45F4-90D0-5E1349A2CF1B @default.
- Q91971437 P2093 Q91971437-7A8FD5FE-5EB3-4A73-B303-51D3A8718C7C @default.
- Q91971437 P2093 Q91971437-BED61292-C969-4BA3-9A9D-3C63A5CFFFFC @default.
- Q91971437 P2093 Q91971437-D98E565D-3315-48EF-8914-D7CAA7682EF2 @default.
- Q91971437 P2093 Q91971437-DF0A1C39-EECA-458E-BF3F-AA629FEA9444 @default.
- Q91971437 P2093 Q91971437-EFD49D6C-E88F-4A6D-9E3D-C699A4CF9972 @default.
- Q91971437 P2093 Q91971437-EFF92716-D446-42D5-A12F-C7A43C8A8F34 @default.
- Q91971437 P304 Q91971437-8441460E-EFC6-41D5-9193-1A8FB53E659B @default.
- Q91971437 P31 Q91971437-F7F31689-4DCE-4B5D-858F-1EB350DB3BF4 @default.
- Q91971437 P356 Q91971437-BBCDD96D-A46B-4D7C-966F-39AD52B23490 @default.
- Q91971437 P433 Q91971437-C7A6DF01-BE49-44D3-8C8C-B61431ACC078 @default.
- Q91971437 P478 Q91971437-34E8AE21-C006-41B6-90A8-C2568F15091A @default.
- Q91971437 P577 Q91971437-CB5BBBFA-A2E9-41D2-A3F5-57FDE71F97CB @default.
- Q91971437 P698 Q91971437-CE3A86C6-10C5-4773-B436-3D1C1DB5D4EA @default.
- Q91971437 P356 J.JAAD.2019.12.002 @default.
- Q91971437 P698 31836564 @default.
- Q91971437 P1433 Q15757046 @default.
- Q91971437 P1476 "Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial" @default.
- Q91971437 P2093 "Adam Mattox" @default.
- Q91971437 P2093 "Anastasia Kurta" @default.
- Q91971437 P2093 "Eric Armbrecht" @default.
- Q91971437 P2093 "Geoffrey A Potts" @default.
- Q91971437 P2093 "Jordan B Slutsky" @default.
- Q91971437 P2093 "Kristen Polito" @default.
- Q91971437 P2093 "M Yadira Hurley" @default.
- Q91971437 P2093 "Melinda B Chu" @default.
- Q91971437 P2093 "Nicole M Burkemper" @default.
- Q91971437 P2093 "Scott W Fosko" @default.
- Q91971437 P2093 "Tim Galperin" @default.
- Q91971437 P304 "946-954" @default.
- Q91971437 P31 Q13442814 @default.
- Q91971437 P356 "10.1016/J.JAAD.2019.12.002" @default.
- Q91971437 P433 "4" @default.
- Q91971437 P478 "82" @default.
- Q91971437 P577 "2019-12-10T00:00:00Z" @default.
- Q91971437 P698 "31836564" @default.